Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The US government's recent raft of pre-emptive measures in favor of flu vaccine R&D and stockpiling may seem like a new window of opportunity for the biotech industry, but they won't necessarily foster innovative vaccines.
Forget everything you know about biotech venture creation—this is Russia! And Dmitry Morosov is one of a new breed of entrepreneurs ready to create a new type of Russian biotech.
Desperate patients are travelling abroad for dubious stem cell therapies. Monya Baker investigates the potential damage not only to human lives but to reputable stem cell research.